GR3035636T3 - Isolated peptides derived from mage tumor rejection antigen precursors which complex with hla-a2 molecules - Google Patents

Isolated peptides derived from mage tumor rejection antigen precursors which complex with hla-a2 molecules

Info

Publication number
GR3035636T3
GR3035636T3 GR20010400481T GR20010400481T GR3035636T3 GR 3035636 T3 GR3035636 T3 GR 3035636T3 GR 20010400481 T GR20010400481 T GR 20010400481T GR 20010400481 T GR20010400481 T GR 20010400481T GR 3035636 T3 GR3035636 T3 GR 3035636T3
Authority
GR
Greece
Prior art keywords
hla
molecules
complex
peptides derived
isolated peptides
Prior art date
Application number
GR20010400481T
Other languages
English (en)
Inventor
Alan Townsend
Judy Bastin
Thierry Boon-Falleur
Der Bruggen Pierrce Van
Pierre Coulie
Thomas Gajewski
Cornelis J M Melief
M W Visseren
W M Kast
Original Assignee
Ludwig Inst Cancer Res
Univ Oxford
Univ Leiden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/217,186 external-priority patent/US5585461A/en
Application filed by Ludwig Inst Cancer Res, Univ Oxford, Univ Leiden filed Critical Ludwig Inst Cancer Res
Publication of GR3035636T3 publication Critical patent/GR3035636T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
GR20010400481T 1994-03-24 2001-03-26 Isolated peptides derived from mage tumor rejection antigen precursors which complex with hla-a2 molecules GR3035636T3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/217,186 US5585461A (en) 1994-03-24 1994-03-24 Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US08/261,160 US5591430A (en) 1994-03-24 1994-06-17 Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US08/290,381 US5851523A (en) 1994-03-24 1994-08-15 Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof
PCT/US1995/003657 WO1995025740A1 (en) 1994-03-24 1995-03-22 Isolated peptides derived from mage tumor rejection antigen precursors which complex with hla-a2 molecules

Publications (1)

Publication Number Publication Date
GR3035636T3 true GR3035636T3 (en) 2001-06-29

Family

ID=27396385

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20010400481T GR3035636T3 (en) 1994-03-24 2001-03-26 Isolated peptides derived from mage tumor rejection antigen precursors which complex with hla-a2 molecules

Country Status (16)

Country Link
US (1) US5851523A (el)
EP (2) EP0960622A3 (el)
JP (1) JP3536179B2 (el)
CN (1) CN1151170C (el)
AT (1) ATE198336T1 (el)
AU (1) AU698781B2 (el)
CA (1) CA2186004C (el)
DE (1) DE69519748T2 (el)
DK (1) DK0804483T3 (el)
ES (1) ES2154728T3 (el)
FI (1) FI963779A7 (el)
GR (1) GR3035636T3 (el)
NO (1) NO963919L (el)
NZ (1) NZ283587A (el)
PT (1) PT804483E (el)
WO (1) WO1995025740A1 (el)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723832B1 (en) * 1996-10-03 2004-04-20 Ludwig Institute For Cancer Research Isolated peptides corresponding to amino acid sequences of NY-ESO-1, which bind to MHC Class I and MHC Class II molecules, and uses thereof
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
US5587289A (en) * 1995-03-14 1996-12-24 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which are members of the MAGE-Xp family and uses thereof
US5821122A (en) * 1995-06-07 1998-10-13 Inserm (Institute Nat'l De La Sante Et De La Recherche . .) Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof
EP0785274B1 (en) * 1996-01-18 2000-09-27 Aventis Pharma Deutschland GmbH An artifical recombinant substrate (rAGG-1) and native aggrecan to study the proteolytic activity of 'Aggrecanase' in cell culture systems
CN1313481C (zh) * 1997-06-23 2007-05-02 路德维格癌症研究所 结合hla分子的分离的九肽和十肽及其应用
US6060284A (en) 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
US6716809B1 (en) 1997-09-12 2004-04-06 Ludwig Institute For Cancer Research Mage-A3 peptides presented by HLA class molecules
US6291430B1 (en) 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
US5965535A (en) 1997-09-12 1999-10-12 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
GB9826143D0 (en) 1998-11-27 1999-01-20 Ludwig Inst Cancer Res Tumour rejection antigens
EP1905832A3 (en) * 1999-09-09 2009-09-09 Schering Corporation Mammalian interleukin-12 P40 and interleukin B30, combinations thereof, antibodies, uses in pharmaceutical compositions
CA2388562C (en) * 1999-09-09 2014-07-22 Schering Corporation Mammalian cytokines; related reagents and methods
US7090847B1 (en) * 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
HK1046925A1 (zh) * 1999-10-19 2003-01-30 Ludwig Institute For Cancer Research Mage-a12抗原肽及其用途
US6897288B1 (en) 1999-10-19 2005-05-24 Ludwig Institute For Cancer Research Mage-A12 antigenic peptides and uses thereof
DK1282702T3 (da) 2000-05-10 2007-04-02 Sanofi Pasteur Ltd Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf
US7049413B2 (en) 2001-05-18 2006-05-23 Ludwig Institute For Cancer Research MAGE-A3 peptides presented by HLA class II molecules
US20030113919A1 (en) * 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
EP1864691B1 (en) 2002-04-09 2011-07-20 Sanofi Pasteur Limited Modified CEA nucleic acid and expression vectors
AU2004280608B2 (en) * 2002-04-09 2012-04-05 Sanofi Pasteur, Inc. Modified CEA/B7 vector
WO2004037284A1 (en) * 2002-10-22 2004-05-06 Sanofi Pasteur Limited Anti-cancer vaccines and high-dose cytokines as adjuvants
KR20100061477A (ko) * 2007-09-11 2010-06-07 몬도바이오테크 래보래토리즈 아게 치료제로서의 펩티드 ａｓｎ-ａｓｐ-ａｓｐ-ｃｙｓ-ｇｌｕ-ｌｅｕ-ｃｙｓ-ｖａｌ-ａｓｎ-ｖａｌ-ａｌａ-ｃｙｓ-ｔｈｒ-ｇｌｙ-ｃｙｓ-ｌｅｕ-ｏｈ 단독 또는 펩티드 ｔｈｒ-ｔｈｒ-ｓｅｒ-ｇｌｎ-ｖａｌ-ａｒｇ-ｐｒｏ-ａｒｇ-ｏｈ와의 배합물의 용도
CN106117334B (zh) * 2016-06-24 2020-02-11 秦皇岛未名健康城开发有限公司 一种肿瘤抗原mage3的ctl识别表位肽及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
AU4998993A (en) * 1992-08-07 1994-03-03 Epimmune, Inc. Hla binding peptides and their uses
US5519117A (en) * 1992-12-22 1996-05-21 Ludwig Institute For Cancer Research Isolated, tyrosinase derived peptides and uses thereof
CN1118572A (zh) * 1993-03-05 1996-03-13 萨依特尔有限公司 Hla-a2.1组合肽及其用途

Also Published As

Publication number Publication date
FI963779A0 (fi) 1996-09-23
CN1150805A (zh) 1997-05-28
ES2154728T3 (es) 2001-04-16
CN1151170C (zh) 2004-05-26
AU698781B2 (en) 1998-11-05
NZ283587A (en) 1998-04-27
NO963919L (no) 1996-11-20
CA2186004A1 (en) 1995-09-28
DK0804483T3 (da) 2001-02-12
NO963919D0 (no) 1996-09-19
US5851523A (en) 1998-12-22
PT804483E (pt) 2001-06-29
DE69519748T2 (de) 2001-10-18
EP0804483A1 (en) 1997-11-05
EP0804483A4 (en) 1998-05-20
EP0960622A2 (en) 1999-12-01
WO1995025740A1 (en) 1995-09-28
CA2186004C (en) 2008-09-23
JPH10504518A (ja) 1998-05-06
FI963779L (fi) 1996-09-23
AU2192895A (en) 1995-10-09
EP0960622A3 (en) 1999-12-22
DE69519748D1 (de) 2001-02-01
FI963779A7 (fi) 1996-09-23
ATE198336T1 (de) 2001-01-15
JP3536179B2 (ja) 2004-06-07
EP0804483B1 (en) 2000-12-27

Similar Documents

Publication Publication Date Title
GR3035636T3 (en) Isolated peptides derived from mage tumor rejection antigen precursors which complex with hla-a2 molecules
NZ335485A (en) Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
DE69940671D1 (de) Mage-a3 polypeptide die durch hla-klasse ii molekule präsentiert werden
IL193886A (en) Antibodies that bind to ldcam sequences
IL107951A0 (en) Mammalian receptors for interleukin-10 (il-10)
DE69435292D1 (de) Verfahren zur herstellung von immunogenen hla-a2.1-bindenden peptiden
AU6632496A (en) Cell derived antigen presenting vesicles
DE69840868D1 (de) Mage-3 peptide, die durch hla-klasse-ii molecule presentiert werden
NZ502391A (en) Mammalian cytokine: interleukin-B30 and related reagents
ATE310097T1 (de) Verfahren zur herstellung rekombinanter adeno- associated viren (aav) und deren verwendung
GR3036320T3 (en) Isolated tumor rejection antigen precursor mage-2 derived peptides, and uses thereof
IL132496A0 (en) Mammalian cytokine-like factor 7
NZ296748A (en) Peripheral nervous system specific sodium channel proteins, DNA coding therefor, compositions and methods
HU9601448D0 (en) Novel apoptosis-modulating proteins, dna encoding the proteins and methods of use thereof
IL111479A0 (en) Chimeric proteins comprising borrelia polypetides and uses therefor
ES545725A0 (es) Procedimiento para preparar peptidos de interferon
WO2000015798A3 (en) Mammalian transforming growth factor beta - 9 (ztgfss9)
PT97355A (pt) Processo para a preparacao de polipeptidos recombinantes contendo uma sequencia de aminoacidos de uma proteina de celulas
WO1998057983A3 (en) Mammalian neuro-growth factor like protein
EP0990703A4 (en) NEW POLYPEPTIDE, FOR CODING DNA AND THEIR USE
IL130164A0 (en) Mammalian chemokines
ZA971403B (en) Tumor rejection antigens presented by HLA-B44 molecules, and uses thereof.
AU3931599A (en) Basb019 proteins and genes from (moraxella catarrhalis), antigens, antibodies, and uses
IL139951A0 (en) Basbo27 proteins and genes from moraxella catarrhalis, intigens, antibodies and uses
SE9002213D0 (sv) Albumin binding proteins